Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impacts of Psychosis and Antipsychotics on Cerebral Energy Metabolism: the ATP Project (Antipsychotic-TEP-Psychosis)

NCT06651112 is registered in ClinicalTrials.gov with Université de Sherbrooke as lead sponsor.

NCT NCT06651112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06651112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impacts of Psychosis and Antipsychotics on Cerebral Energy Metabolism: the ATP Project (Antipsychotic-TEP-Psychosis)
Lead sponsor
Université de Sherbrooke
Phase
Observational
Overall status
Not yet recruiting
Start date
November 1, 2024
Completion date
June 1, 2027
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

first episose psychosis, metabolic disease, psychosis; episode